Alzheimer's disease drug development pipeline: 2025
Abstract Clinical trials for Alzheimer's disease (AD) must be registered on clinicaltrials.gov. The registry presents a variety of types of information related to the planned clinical trial. We assess clinicaltrials.gov to document and compare aspects of drug development across the AD pipeline....
Saved in:
| Main Authors: | Jeffrey L. Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Fonseca, Amanda M. Leisgang‐Osse, Feixiong Cheng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.70098 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization
by: Amanda M. Leisgang Osse, et al.
Published: (2025-01-01) -
Alzheimer's disease drug development pipeline: 2019
by: Jeffrey Cummings, et al.
Published: (2019-01-01) -
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting
by: Ronald C. Petersen, et al.
Published: (2025-01-01) -
Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice
by: Clifford R. Jack, et al.
Published: (2024-10-01) -
Enrichment factors for clinical trials in mild‐to‐moderate Alzheimer's disease
by: Clive Ballard, et al.
Published: (2019-01-01)